Group 1 - The core viewpoint of the article highlights that Peijia Medical (9996.HK) experienced a significant stock price increase of 8.26%, reaching a new high of 6.29 HKD since October 21, indicating positive market sentiment [1] - Peijia Medical announced the approval of its TaurusTrio™ transcatheter aortic valve (TAV) system by the National Medical Products Administration of China, with expectations for successful market entry by December 11, 2025, addressing a major unmet clinical need for patients with severe aortic regurgitation (AR) in China [1] - The company's CEO and Chairman, Zhang Yi, has begun purchasing company shares in the open market since December 1, 2025, with a total investment not exceeding 15 million HKD, reflecting confidence in the company's intrinsic value and growth potential [1]
港股异动丨沛嘉医疗-B涨超8% 股价创近2个月新高